Patents by Inventor Scott R. Daigle

Scott R. Daigle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
    Publication number: 20210252035
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 10, 2020
    Publication date: August 19, 2021
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott R. DAIGLE
  • DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
    Publication number: 20200113923
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 16, 2020
    Inventors: Roy M. Pollock, Scott R. Daigle
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20200009176
    Abstract: The present invention relates to DOT1L inhibitors.
    Type: Application
    Filed: May 17, 2019
    Publication date: January 9, 2020
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • Combination therapy for treating cancer
    Patent number: 10525074
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 7, 2020
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20190076455
    Abstract: The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 14, 2019
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • Methods for treating cancer
    Patent number: 10143704
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 4, 2018
    Assignee: Epizyme, Inc.
    Inventors: Roy M. Pollock, Scott R. Daigle, Eric Hedrick, Nigel Waters, Blythe Thomson
  • SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
    Publication number: 20180280422
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 4, 2018
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin Wayne KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott R. DAIGLE
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20170080010
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 23, 2017
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • METHODS FOR TREATING CANCER
    Publication number: 20160296548
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 13, 2016
    Inventors: Roy M. Pollock, Scott R. Daigle, Eric Hedrick, Nigel Waters, Blythe Thomson
  • Combination therapy for treating cancer
    Patent number: 9446064
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
    Publication number: 20150366893
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 24, 2015
    Applicant: EPIZYME, INC.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin Wayne Kuntz, Victoria M. Richon, Roy M. Pollock, Scott R. Daigle
  • DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
    Publication number: 20150342979
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 3, 2015
    Inventors: Roy M. Pollock, Scott R. Daigle
  • Substituted purine and 7-deazapurine compounds
    Patent number: 9096634
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 4, 2015
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott R. Daigle
  • Combination Therapy for Treating Cancer
    Publication number: 20140323421
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicant: EPIZYME, INC.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Substituted Purine and 7-Deazapurine Compounds
    Publication number: 20140051654
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: October 16, 2013
    Publication date: February 20, 2014
    Applicant: EPIZYME, INC.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott R. Daigle
  • Substituted Purine And 7-Deazapurine Compounds
    Publication number: 20120142625
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 2, 2011
    Publication date: June 7, 2012
    Applicant: EPIZYME, INC.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott R. Daigle